- •Contents
- •Contributors
- •Part I General Principles of Cell Death
- •1 Human Caspases – Apoptosis and Inflammation Signaling Proteases
- •1.1. Apoptosis and limited proteolysis
- •1.2. Caspase evolution
- •2. ACTIVATION MECHANISMS
- •2.2. The activation platforms
- •2.4. Proteolytic maturation
- •3. CASPASE SUBSTRATES
- •4. REGULATION BY NATURAL INHIBITORS
- •REFERENCES
- •2 Inhibitor of Apoptosis Proteins
- •2. CELLULAR FUNCTIONS AND PHENOTYPES OF IAP
- •3. IN VIVO FUNCTIONS OF IAP FAMILY PROTEINS
- •4. SUBCELLULAR LOCATIONS OF IAP
- •8. IAP–IAP INTERACTIONS
- •10. ENDOGENOUS ANTAGONISTS OF IAP
- •11. IAPs AND DISEASE
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2.1. The CD95 (Fas/APO-1) system
- •2.1.1. CD95 and CD95L: discovery of the first direct apoptosis-inducing receptor-ligand system
- •2.1.2. Biochemistry of CD95 apoptosis signaling
- •2.2. The TRAIL (Apo2L) system
- •3.1. The TNF system
- •3.1.1. Biochemistry of TNF signal transduction
- •3.1.2. TNF and TNF blockers in the clinic
- •3.2. The DR3 system
- •4. THE DR6 SYSTEM
- •6. CONCLUDING REMARKS AND OUTLOOK
- •SUGGESTED READINGS
- •4 Mitochondria and Cell Death
- •1. INTRODUCTION
- •2. MITOCHONDRIAL PHYSIOLOGY
- •3. THE MITOCHONDRIAL PATHWAY OF APOPTOSIS
- •9. CONCLUSIONS
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •3. INHIBITING APOPTOSIS
- •4. INHIBITING THE INHIBITORS
- •6. THE BCL-2 FAMILY AND CANCER
- •SUGGESTED READINGS
- •6 Endoplasmic Reticulum Stress Response in Cell Death and Cell Survival
- •1. INTRODUCTION
- •2. THE ESR IN YEAST
- •3. THE ESR IN MAMMALS
- •4. THE ESR AND CELL DEATH
- •5. THE ESR IN DEVELOPMENT AND TISSUE HOMEOSTASIS
- •6. THE ESR IN HUMAN DISEASE
- •7. CONCLUSION
- •7 Autophagy – The Liaison between the Lysosomal System and Cell Death
- •1. INTRODUCTION
- •2. AUTOPHAGY
- •2.2. Physiologic functions of autophagy
- •2.3. Autophagy and human pathology
- •3. AUTOPHAGY AND CELL DEATH
- •3.1. Autophagy as anti–cell death mechanism
- •3.2. Autophagy as a cell death mechanism
- •3.3. Molecular players of the autophagy–cell death cross-talk
- •4. AUTOPHAGY, CELLULAR DEATH, AND CANCER
- •5. CONCLUDING REMARKS AND PENDING QUESTIONS
- •SUGGESTED READINGS
- •8 Cell Death in Response to Genotoxic Stress and DNA Damage
- •1. TYPES OF DNA DAMAGE AND REPAIR SYSTEMS
- •2. DNA DAMAGE RESPONSE
- •2.2. Transducers
- •2.3. Effectors
- •4. CHROMATIN MODIFICATIONS
- •5. CELL CYCLE CHECKPOINT REGULATION
- •6. WHEN REPAIR FAILS: SENESCENCE VERSUS APOPTOSIS
- •6.1. DNA damage response and the induction of apoptosis
- •6.2. p53-independent mechanisms of apoptosis
- •6.3. DNA damage response and senescence induction
- •7. DNA DAMAGE FROM OXIDATIVE STRESS
- •SUGGESTED READINGS
- •9 Ceramide and Lipid Mediators in Apoptosis
- •1. INTRODUCTION
- •3.1. Basic cell signaling often involves small molecules
- •3.2. Sphingolipids are cell-signaling molecules
- •3.2.1. Ceramide induces apoptosis
- •3.2.2. Ceramide accumulates during programmed cell death
- •3.2.3. Inhibition of ceramide production alters cell death signaling
- •4.1. Ceramide is generated through SM hydrolysis
- •4.3. aSMase can be activated independently of extracellular receptors to regulate apoptosis
- •4.4. Controversial aspects of the role of aSMase in apoptosis
- •4.5. De novo ceramide synthesis regulates programmed cell death
- •4.6. p53 and Bcl-2–like proteins are connected to de novo ceramide synthesis
- •4.7. The role and regulation of de novo synthesis in ceramide-mediated cell death is poorly understood
- •5. CONCLUDING REMARKS AND FUTURE DIRECTIONS
- •5.1. Who? (Which enzyme?)
- •5.2. What? (Which ceramide?)
- •5.3. Where? (Which compartment?)
- •5.4. When? (At what steps?)
- •5.5. How? (Through what mechanisms?)
- •5.6. What purpose?
- •6. SUMMARY
- •SUGGESTED READINGS
- •1. General Introduction
- •1.1. Cytotoxic lymphocytes and apoptosis
- •2. CYTOTOXIC GRANULES AND GRANULE EXOCYTOSIS
- •2.1. Synthesis and loading of the cytotoxic granule proteins into the secretory granules
- •2.2. The immunological synapse
- •2.3. Secretion of granule proteins
- •2.4. Uptake of proapoptotic proteins into the target cell
- •2.5. Activation of death pathways by granzymes
- •3. GRANULE-BOUND CYTOTOXIC PROTEINS
- •3.1. Perforin
- •3.2. Granulysin
- •3.3. Granzymes
- •3.3.1. GrB-mediated apoptosis
- •3.3.2. GrA-mediated cell death
- •3.3.3. Orphan granzyme-mediated cell death
- •5. CONCLUSIONS
- •REFERENCES
- •Part II Cell Death in Tissues and Organs
- •1.1. Death by trophic factor deprivation
- •1.2. Key molecules regulating neuronal apoptosis during development
- •1.2.1. Roles of caspases and Apaf-1 in neuronal cell death
- •1.2.2. Role of Bcl-2 family members in neuronal cell death
- •1.3. Signal transduction from neurotrophins and neurotrophin receptors
- •1.3.1. Signals for survival
- •1.3.2. Signals for death
- •2.1. Apoptosis in neurodegenerative diseases
- •2.1.4. Amyotrophic lateral sclerosis
- •2.2. Necrotic cell death in neurodegenerative diseases
- •2.2.1. Calpains
- •2.2.2. Cathepsins
- •3. CONCLUSIONS
- •ACKNOWLEDGMENT
- •SUGGESTED READINGS
- •ACKNOWLEDGMENT
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •5. S-NITROSYLATION OF PARKIN
- •7. POTENTIAL TREATMENT OF EXCESSIVE NMDA-INDUCED Ca2+ INFLUX AND FREE RADICAL GENERATION
- •8. FUTURE THERAPEUTICS: NITROMEMANTINES
- •9. CONCLUSIONS
- •Acknowledgments
- •SUGGESTED READINGS
- •3. MITOCHONDRIAL PERMEABILITY TRANSITION ACTIVATED BY Ca2+ AND OXIDATIVE STRESS
- •4.1. Mitochondrial apoptotic pathways
- •4.2. Bcl-2 family proteins
- •4.3. Caspase-dependent apoptosis
- •4.4. Caspase-independent apoptosis
- •4.5. Calpains in ischemic neural cell death
- •5. SUMMARY
- •ACKNOWLEDGMENTS
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2. HISTORICAL ANTECEDENTS
- •7.1. Activation of p21 waf1/cip1: Targeting extrinsic and intrinsic pathways to death
- •8. CONCLUSION
- •ACKNOWLEDGMENTS
- •REFERENCES
- •16 Apoptosis and Homeostasis in the Eye
- •1.1. Lens
- •1.2. Retina
- •2. ROLE OF APOPTOSIS IN DISEASES OF THE EYE
- •2.1. Glaucoma
- •2.2. Age-related macular degeneration
- •4. APOPTOSIS AND OCULAR IMMUNE PRIVILEGE
- •5. CONCLUSIONS
- •SUGGESTED READINGS
- •17 Cell Death in the Inner Ear
- •3. THE COCHLEA IS THE HEARING ORGAN
- •3.1. Ototoxic hair cell death
- •3.2. Aminoglycoside-induced hair cell death
- •3.3. Cisplatin-induced hair cell death
- •3.4. Therapeutic strategies to prevent hair cell death
- •3.5. Challenges to studies of hair cell death
- •4. SPIRAL GANGLION NEURON DEATH
- •4.1. Neurotrophic support from sensory hair cells and supporting cells
- •4.2. Afferent activity from hair cells
- •4.3. Molecular manifestations of spiral ganglion neuron death
- •4.4. Therapeutic interventions to prevent SGN death
- •ACKNOWLEDGMENTS
- •SUGGESTED READINGS
- •18 Cell Death in the Olfactory System
- •1. Introduction
- •2. Anatomical Aspects
- •3. Life and Death in the Olfactory System
- •3.1. Olfactory epithelium
- •3.2. Olfactory bulb
- •REFERENCES
- •1. Introduction
- •3.1. Beta cell death in the development of T1D
- •3.2. Mechanisms of beta cell death in type 1 diabetes
- •3.2.1. Apoptosis signaling pathways downstream of death receptors and inflammatory cytokines
- •3.2.2. Oxidative stress
- •3.3. Mechanisms of beta cell death in type 2 diabetes
- •3.3.1. Glucolipitoxicity
- •3.3.2. Endoplasmic reticulum stress
- •5. SUMMARY
- •Acknowledgments
- •REFERENCES
- •20 Apoptosis in the Physiology and Diseases of the Respiratory Tract
- •1. APOPTOSIS IN LUNG DEVELOPMENT
- •2. APOPTOSIS IN LUNG PATHOPHYSIOLOGY
- •2.1. Apoptosis in pulmonary inflammation
- •2.2. Apoptosis in acute lung injury
- •2.3. Apoptosis in chronic obstructive pulmonary disease
- •2.4. Apoptosis in interstitial lung diseases
- •2.5. Apoptosis in pulmonary arterial hypertension
- •2.6. Apoptosis in lung cancer
- •SUGGESTED READINGS
- •21 Regulation of Cell Death in the Gastrointestinal Tract
- •1. INTRODUCTION
- •2. ESOPHAGUS
- •3. STOMACH
- •4. SMALL AND LARGE INTESTINE
- •5. LIVER
- •6. PANCREAS
- •7. SUMMARY AND CONCLUDING REMARKS
- •SUGGESTED READINGS
- •22 Apoptosis in the Kidney
- •1. NORMAL KIDNEY STRUCTURE AND FUNCTION
- •3. APOPTOSIS IN ADULT KIDNEY DISEASE
- •4. REGULATION OF APOPTOSIS IN KIDNEY CELLS
- •4.1. Survival factors
- •4.2. Lethal factors
- •4.2.1. TNF superfamily cytokines
- •4.2.2. Other cytokines
- •4.2.3. Glucose
- •4.2.4. Drugs and xenobiotics
- •4.2.5. Ischemia-reperfusion and sepsis
- •5. THERAPEUTIC APPROACHES
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2. APOPTOSIS IN THE NORMAL BREAST
- •2.1. Occurrence and role of apoptosis in the developing breast
- •2.2.2. Death ligands and death receptor pathway
- •2.2.4. LIF-STAT3 proapoptotic signaling
- •2.2.5. IGF survival signaling
- •2.2.6. Regulation by adhesion
- •2.2.7. PI3K/AKT pathway: molecular hub for survival signals
- •2.2.8. Downstream regulators of apoptosis: the BCL-2 family members
- •3. APOPTOSIS IN BREAST CANCER
- •3.1. Apoptosis in breast tumorigenesis and cancer progression
- •3.2. Molecular dysregulation of apoptosis in breast cancer
- •3.2.1. Altered expression of death ligands and their receptors in breast cancer
- •3.2.2. Deregulation of prosurvival growth factors and their receptors
- •3.2.3. Alterations in cell adhesion and resistance to anoikis
- •3.2.4. Enhanced activation of the PI3K/AKT pathway in breast cancer
- •3.2.5. p53 inactivation in breast cancer
- •3.2.6. Altered expression of BCL-2 family of proteins in breast cancer
- •5. CONCLUSION
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2. DETECTING CELL DEATH IN THE FEMALE GONADS
- •4. APOPTOSIS AND FEMALE REPRODUCTIVE AGING
- •6. CONCLUDING REMARKS
- •REFERENCES
- •25 Apoptotic Signaling in Male Germ Cells
- •1. INTRODUCTION
- •3.1. Murine models
- •3.2. Primate models
- •3.3. Pathways of caspase activation and apoptosis
- •3.4. Apoptotic signaling in male germ cells
- •5. P38 MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) AND NITRIC OXIDE (NO)–MEDIATED INTRINSIC PATHWAY SIGNALING CONSTITUTES A CRITICAL COMPONENT OF APOPTOTIC SIGNALING IN MALE GERM CELLS AFTER HORMONE DEPRIVATION
- •11. CONCLUSIONS AND PERSPECTIVES
- •REFERENCES
- •26 Cell Death in the Cardiovascular System
- •1. INTRODUCTION
- •2. CELL DEATH IN THE VASCULATURE
- •2.1. Apoptosis in the developing blood vessels
- •2.2. Apoptosis in atherosclerosis
- •2.2.1. Vascular smooth muscle cells
- •2.2.2. Macrophages
- •2.2.3. Regulation of apoptosis in atherosclerosis
- •2.2.4. Necrosis and autophagy in atherosclerosis
- •3. CELL DEATH IN THE MYOCARDIUM
- •3.1. Cell death in myocardial infarction
- •3.1.1. Apoptosis in myocardial infarction
- •3.1.2. Necrosis in myocardial infarction
- •3.1.3. Autophagy in myocardial infarction
- •3.2. Cell death in heart failure
- •3.2.1. Apoptosis in heart failure
- •3.2.2. Necrosis in heart failure
- •3.2.3. Autophagy in heart failure
- •4. CONCLUDING REMARKS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •27 Cell Death Regulation in Muscle
- •1. INTRODUCTION TO MUSCLE
- •1.1. Skeletal muscle adaptation to endurance training
- •1.2. Myonuclear domains
- •2. MITOCHONDRIALLY MEDIATED APOPTOSIS IN MUSCLE
- •2.1. Skeletal muscle apoptotic susceptibility
- •4. APOPTOSIS IN MUSCLE DURING AGING AND DISEASE
- •4.1. Aging
- •4.2. Type 2 diabetes mellitus
- •4.3. Cancer cachexia
- •4.4. Chronic heart failure
- •6. CONCLUSION
- •SUGGESTED READINGS
- •28 Cell Death in the Skin
- •1. INTRODUCTION
- •2. CELL DEATH IN SKIN HOMEOSTASIS
- •2.1. Cornification and apoptosis
- •2.2. Death receptors in the skin
- •3. CELL DEATH IN SKIN PATHOLOGY
- •3.1. Sunburn
- •3.2. Skin cancer
- •3.3. Necrolysis
- •3.4. Pemphigus
- •3.5. Eczema
- •3.6. Graft-versus-host disease
- •4. CONCLUDING REMARKS AND PERSPECTIVES
- •ACKNOWLEDGMENTS
- •SUGGESTED READINGS
- •29 Apoptosis and Cell Survival in the Immune System
- •2.1. Survival of early hematopoietic progenitors
- •2.2. Sizing of the T-cell population
- •2.2.1. Establishing central tolerance
- •2.2.2. Peripheral tolerance
- •2.2.3. Memory T cells
- •2.3. Control of apoptosis in B-cell development
- •2.3.1. Early B-cell development
- •2.3.2. Deletion of autoreactive B cells
- •2.3.3. Survival and death of activated B cells
- •3. IMPAIRED APOPTOSIS AND LEUKEMOGENESIS
- •4. CONCLUSIONS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •30 Cell Death Regulation in the Hematopoietic System
- •1. INTRODUCTION
- •2. HEMATOPOIETIC STEM CELLS
- •4. ERYTHROPOIESIS
- •5. MEGAKARYOPOIESIS
- •6. GRANULOPOIESIS
- •7. MONOPOIESIS
- •8. CONCLUSION
- •ACKNOWLEDGMENTS
- •REFERENCES
- •31 Apoptotic Cell Death in Sepsis
- •1. INTRODUCTION
- •2. HOST INFLAMMATORY RESPONSE TO SEPSIS
- •3. CLINICAL OBSERVATIONS OF CELL DEATH IN SEPSIS
- •3.1. Sepsis-induced apoptosis
- •3.2. Necrotic cell death in sepsis
- •4.1. Central role of apoptosis in sepsis mortality: immune effector cells and gut epithelium
- •4.2. Apoptotic pathways in sepsis-induced immune cell death
- •4.3. Investigations implicating the extrinsic apoptotic pathway in sepsis
- •4.4. Investigations implicating the intrinsic apoptotic pathway in sepsis
- •5. THE EFFECT OF APOPTOSIS ON THE IMMUNE SYSTEM
- •5.1. Cellular effects of an increased apoptotic burdens
- •5.2. Network effects of selective loss of immune cell types
- •5.3. Studies of immunomodulation by apoptotic cells in other fields
- •7. CONCLUSION
- •REFERENCES
- •32 Host–Pathogen Interactions
- •1. INTRODUCTION
- •2. FROM THE PATHOGEN PERSPECTIVE
- •2.1. Commensals versus pathogens
- •2.2. Pathogen strategies to infect the host
- •3. HOST DEFENSE
- •3.1. Antimicrobial peptides
- •3.2. PRRs and inflammation
- •3.2.1. TLRs
- •3.2.2. NLRs
- •3.2.3. The Nod signalosome
- •3.2.4. The inflammasome
- •3.3. Cell death
- •3.3.1. Apoptosis and pathogen clearance
- •3.3.2. Pyroptosis
- •3.2.3. Caspase-independent cell death
- •3.2.4. Autophagy and autophagic cell death
- •4. CONCLUSIONS
- •REFERENCES
- •Part III Cell Death in Nonmammalian Organisms
- •1. PHENOTYPE AND ASSAYS OF YEAST APOPTOSIS
- •2.1. Pheromone-induced cell death
- •2.1.1. Colony growth
- •2.1.2. Killer-induced cell death
- •3. EXTERNAL STIMULI THAT INDUCE APOPTOSIS IN YEAST
- •4. THE GENETICS OF YEAST APOPTOSIS
- •5. PROGRAMMED AND ALTRUISTIC AGING
- •SUGGESTED READINGS
- •34 Caenorhabditis elegans and Apoptosis
- •1. Overview
- •2. KILLING
- •3. SPECIFICATION
- •4. EXECUTION
- •4.1. DNA degradation
- •4.2. Mitochondrial elimination
- •4.3. Engulfment
- •5. SUMMARY
- •SUGGESTED READINGS
- •35 Apoptotic Cell Death in Drosophila
- •2. DROSOPHILA CASPASES AND PROXIMAL REGULATORS
- •6. CLOSING COMMENTS
- •SUGGESTED READINGS
- •36 Analysis of Cell Death in Zebrafish
- •1. INTRODUCTION
- •2. WHY USE ZEBRAFISH TO STUDY CELL DEATH?
- •2.2. Molecular techniques to rapidly assess gene function in embryos
- •2.2.1. Studies of gene function using microinjections into early embryos
- •2.2.2. In situ hybridization and immunohistochemistry
- •2.3. Forward genetic screening
- •2.4. Drug and small-molecule screening
- •2.5. Transgenesis
- •2.6. Targeted knockouts
- •3.1. Intrinsic apoptosis
- •3.2. Extrinsic apoptosis
- •3.3. Chk-1 suppressed apoptosis
- •3.4. Anoikis
- •3.5. Autophagy
- •3.6. Necrosis
- •4. DEVELOPMENTAL CELL DEATH IN ZEBRAFISH EMBRYOS
- •5. THE P53 PATHWAY
- •6. PERSPECTIVES AND FUTURE DIRECTIONS
- •SUGGESTED READING
22 Apoptosis in the Kidney
Juan Antonio Moreno, Adrian Mario Ramos, and Alberto Ortiz
1. NORMAL KIDNEY STRUCTURE AND FUNCTION
The kidneys maintain the homeostasis of electrolyte, fluid, and acid–base balance; eliminate waste products; and have an endocrine-metabolic function. They secrete hormones such as erythropoietin, Klotho, and 1,25-(OH)2-vitamin D and clear other hormones and cytokines. Each kidney contains 1 million basic functional units, or nephrons. Each nephron is composed of a glomerulus and a renal tubule. The glomerulus is a tightly woven, highly permeable capillary bed, surrounded by differentiated, very specialized cells, the podocytes. The mesangium contains mesangial cells and holds the capillaries together. Every day, 180 L of plasma is filtered through the glomeruli. Podocytes prevent the filtration of proteins, and their injury will lead to pathological urinary protein excretion (proteinuria). Podocytes do not divide, and podocyte loss causes podocytopenia, an early event in progressive glomerular scarring. Tubular cells reabsorb most of the filtered fluid and nutrients, and only 1 to 2 L of urine is excreted. Proximal tubular cells are responsible for the bulk of reabsorption. They are rich in mitochondria, consume high amounts of energy, and express a variety of transporters that favor the uptake of nephrotoxins. Thus they are prime targets in toxic and ischemic renal injury.
2. APOPTOSIS IN KIDNEY DEVELOPMENT AND
CONGENITAL KIDNEY DISEASES
Normal nephrogenesis results from finely balanced proliferative and apoptotic cell death processes. The ureteric bud invades the metanephric mesenchyme, branching and promoting the differentiation of the mesenchyme
into nephrons. The metanephric mesenchyme has a default fate of apoptosis that is prevented by factors secreted from the bud, such as transforming growth factor (TGF)-α, epidermal growth factor, fibroblast growth factor 2, and glial cell line–derived neurotrophic factor (GDNF). Genetic evidence from knockout mice indicates that during development, the high expression of Bcl-2 and Pax-2 protects cells against apoptosis, allowing cell proliferation and differentiation. In the mature kidney, Pax-2 is not found, and the expression of Bcl2 is low. Other antiapoptotic molecules, such as Bcl-xl, predominate. However, in the course of renal injury, adult kidneys may re-express some of these antiapoptotic factors in the frame of a more general adaptive response against the aggression.
Bcl-2–deficient mice (bcl-2–/–) are viable. However, they die within a few months of birth from renal failure. Renal hypoplasia and cystic dysplasia resembling polycystic kidney disease (PKD) result from excessive apoptosis in the metanephric blastema and nephrogenic zones. Bim is a key factor in renal injury in bcl-2–/– mice. Normal kidney development is restored in bcl-2–/– bim–/+ chimeric mice. Bim is not required for normal renal development because kidneys from bim–/– mice are normal. This has been explained by the existence of a hierarchic functional axis involving Bim, Bcl-2, and Bak/Bax. Active Bim might initiate the death signaling acting as a sensor setting the apoptotic threshold, whereas Bcl-2 might or might not allow the propagation of death stimulus according to its expression level. Bak/Bax might execute the death program depending on the result of the Bim and Bcl-2 interaction.
Apoptotic loss of cells is a hallmark of renal hypoplasia, a developmental disease with a genetic
240
APOPTOSIS IN THE KIDNEY |
|
241 |
||
|
|
|
|
|
|
Table 22-1. Main renal diseases with renal cell loss by apoptosis |
|
|
|
|
|
|
|
|
|
|
Main cell type |
|
|
|
Renal disease |
undergoing apoptosis |
Main apoptosis inducers |
|
|
|
|
|
|
|
Renal hypoplasia/agenesis |
Metanephric mesenchyme and |
Absence of survival factors |
|
|
|
ureteric bud cells |
|
|
|
Acute kidney injury |
Tubular cells |
Nephrotoxins, ischemia/reperfusion, |
|
|
|
|
inflammatory mediators |
|
|
Chronic kidney disease |
Podocytes, glomerular |
Inflammatory mediators, etiology-specific |
|
|
|
mesangial and endothelial cells, |
factors |
|
|
|
tubular cells |
|
|
|
Diabetic nephropathya |
Podocytes, tubular cells |
High glucose, glucose degradation products, |
|
|
|
|
extracellular matrix alterations, inflammatory |
|
|
|
|
mediators (angiotensin II; TGFβ1, TNF |
|
|
|
|
superfamily cytokines) |
|
|
Vascular renal injurya |
Tubular cells |
Ischemia |
|
|
Glomerular injurya |
Podocytes, mesangial cells |
Inflammatory mediators |
|
|
Polycystic kidney diseasesa |
Tubular cells |
Genes encoding ciliary proteins |
a Diabetic nephropathy, vascular renal injury, glomerular injury, and polycystic kidney diseases are the most frequent causes of CKD.
basis. Homozygous or heterozygous mutations of the antiapoptotic Pax-2 gene result in a variable pathology ranging from bilateral renal agenesis and severe renal hypoplasia to mild renal hypoplasia. Low pax-2 expression does lead to changes in Bcl-2 expression. However, targeted over-expression of Bcl2 reverses the programmed cell death observed in the ureteric bud of pax2–/– mutant mice and restores normal kidney size, nephron number, and renal function. Heterozygous mutations in RET, the GDNF receptor, may result in renal agenesis in humans.
3. APOPTOSIS IN ADULT KIDNEY DISEASE
Disturbances in cell number in which apoptosis is involved have been described in animal models and clinical renal diseases. We review the role and regulation of apoptosis in acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, glomerular injury, and PKD. An imbalance between mitosis/chemotaxis and apoptosis can result in disorders of cell number characterized by an excessive cell number (e.g., proliferative glomerulonephritis) or insufficient cell number (e.g., renal atrophy) (Table 22-1). Although dysregulated fibroblast or leukocyte apoptosis may contribute to renal fibrosis and inflammation, respectively, we concentrate here on parenchymal renal cell apoptosis. Loss of parenchymal renal cells characterizes both AKI and CKD. Podocytes and tubular cells
may be lost by shedding, death, or differentiation into fibroblasts. All of these mechanisms are responses to injury that may coexist and contribute to renal cell loss. To date there is insufficient information on the relative contribution of each of them to cell loss in many disease processes. Apoptosis may be the initial insult that causes renal disease, or it may contribute to progressive renal cell loss. However, apoptosis is also required for tissue remodeling and recovery of normal tissue structure. As an example, redundant cells in proliferative glomerulonephritis are cleared through apoptosis. Thus it is important to understand the kinetics, targets, and mechanisms of apoptosis in preclinical models before planning clinical trials of antiapoptotic drugs in kidney disease (Table 22-2).
AKI is a syndrome characterized by an acute loss of renal function. Because of its time frame, it is the model of kidney injury in which the role and regulation of apoptosis has been most extensively studied. Current therapy of AKI is symptomatic and consists of substitution of renal function by dialysis if renal failure is severe. There is no established therapy to accelerate the recovery, and attempts at preventing AKI are not universally effective. Despite the reversibility of the loss of renal function, the mortality of AKI remains high (>50%). Thus therapies based in a correct understanding of its pathogenesis are urgently needed. In human studies, tubular cell death is the best histological correlate with renal dysfunction in AKI. Evidence supporting a key role of
242 |
|
|
JUAN ANTONIO MORENO, ADRIAN MARIO RAMOS, AND ALBERTO ORTIZ |
||
|
|
|
|
|
|
|
Table 22-2. Role of apoptosis in kidney disease |
|
|
|
|
|
|
|
|
|
|
|
Cell target |
Timing |
Problem |
Consequence |
|
|
|
|
|
|
|
|
Podocytes |
Acute, chronic |
Cell death in nondividing cells |
Podocytopenia, |
|
|
|
|
|
glomerulosclerosis, |
|
|
|
|
|
CKD progression |
|
|
Tubular cells |
Acute, chronic |
Cell death exceeds mitotic |
AKI, tubular atrophy, |
|
|
|
|
potential |
CKD progression |
|
|
Mesangial cells |
Chronic |
Cell death exceeds mitotic |
Glomerulosclerosis, |
|
|
|
|
potential |
CKD progression |
|
|
Mesangial, tubular cells |
Recovery phase (reactive |
Cell death exceeds mitotic |
Restoration of normal cell |
|
|
|
hyperplasia) |
rate transiently to eliminate |
number |
|
|
|
|
excessive cells |
|
|
|
Inflammatory cells |
Acute, chronic |
Insu cient apoptotic |
Persistent inflammation |
|
|
|
|
clearance |
|
|
|
Fibroblasts |
Chronic |
Insu cient apoptotic |
Failure to resolve fibrosis, |
|
|
|
|
clearance |
progressive fibrosis, |
|
|
|
|
|
CKD progression |
|
|
|
|
|||
|
Note: Apoptosis may be beneficial or deleterious in the course of kidney disease, depending on the magnitude of the phenomenon, the |
|
|||
|
timing, and the cell target. Eventual antiapoptotic therapies should be targeted to a particular cell type, lethal stimulus, and time frame as |
|
|||
|
narrowly as possible. |
|
|
|
|
|
|
|
|
|
|
tubular cell death in the pathogenesis of AKI includes the fact that several nephrotoxins that induce AKI also promote tubular cell death in culture, that therapeutic intervention on apoptosis improves experimental AKI, and that a bioartificial kidney containing proximal tubular cells improves survival in experimental animals and, in preliminary studies, in humans. Tubular cell death in the early stages of AKI of different etiologies (ischemic, toxic, septic, obstructive) can proceed through apoptosis or necrosis. The relative contribution of the two mechanisms to tubular cell loss depends on the severity of the insult. A second peak of apoptosis occurs days (it peaks at day 8 in rat ischemic AKI) after the original insult, when the injured tubules have been completely reconstituted by a hyperplastic epithelium. In this case, apoptosis restores cell number to preinjury levels.
In CKD, progressive loss of renal mass and function leads to end-stage renal disease, necessitating replacement of renal function by dialysis or transplantation. The personal, social, and economic costs of these therapies are staggering at approximately 20 billion US dollars per year in the United States. Apoptotic cell death exceeding mitotic replacement contributes to renal cell loss in the form of podocytopenia, glomerulosclerosis, and tubular atrophy. This has been documented for podocytes and mesangial, endothelial, and tubular cells in experimental models of progressive glomerular scarring and tubulointerstitial atrophy. Consistent with the experimental data, an increased rate of apoptosis has been observed in human CKD.
Diabetic nephropathy, vascular injury, glomerular injury, and PKD are frequent causes of CKD. Diabetic nephropathy is the most common cause of end-stage renal disease. Hyperglycemia is the primary metabolic alteration that promotes diabetic tissue injury. However, glucose degradation products and elevated local cytokine (e.g., tumor necrosis factor [TNF], TNF-related apoptosis-inducing ligand [TRAIL]; TGFβ1, angiotensin II) levels also contribute to tissue injury and renal cell apoptosis (Figure 22-1). The glomerulus was long thought to be the primary site of injury in diabetic nephropathy. Recently, podocytopenia was identified as an early feature of diabetic nephropathy and podocyte apoptosis as a primary contributor. In addition, tubular cell apoptosis is prominent in diabetic nephropathy. The expression of 112 cell death–related genes was abnormal in the tubulointerstitium of diabetic nephropathy patients, and diabetic individuals are sensitized to AKI. One hypothesis attributes the sensitization to AKI to an abnormal pattern of apoptotic gene expression that favors renal cell death.
Other forms of glomerular injury are usually the result of immune or inflammatory aggression. Inflammatory mediators may cause mesangial, glomerular endothelial cell, and podocyte apoptosis, ultimately leading to glomerular scarring (glomerulosclerosis). TGFβ1, angiotensin II, a high glucose concentration, mechanical stress (which may result from increased single-nephron glomerular filtration rate in remnant